Supernus Pharmaceuticals Ownership | Who Owns Supernus Pharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

Supernus Pharmaceuticals Ownership Summary


Supernus Pharmaceuticals is owned by 105.99% institutional investors, 4.19% insiders. Blackrock is the largest institutional shareholder, holding 18.90% of SUPN shares. iShares Core S&P Small-Cap ETF is the top mutual fund, with 5.98% of its assets in Supernus Pharmaceuticals shares.

SUPN Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockSupernus Pharmaceuticals105.99%4.19%-10.18%
SectorHealthcare Stocks 488.17%11.08%-399.26%
IndustrySpecialty & Generic Drug Manufacturers Stocks43.51%11.55%44.95%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock10.39M18.90%$278.00M
Blackrock funding, inc. /de9.37M16.72%$295.28M
Vanguard group6.15M11.15%$222.41M
Armistice capital4.81M8.59%$151.67M
Dimensional fund advisors lp2.88M5.22%$104.09M
Macquarie group2.63M4.77%$95.06M
State street2.16M3.94%$57.88M
Renaissance1.60M2.90%$57.81M
Pacer advisors1.60M2.90%$57.76M
Stephens investment management group1.58M2.82%$49.84M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Krensavage asset management472.38K7.88%$14.89M
Armistice capital4.81M2.62%$151.67M
Ashford capital management711.89K2.57%$19.04M
Sofinnova investments799.25K1.54%$25.19M
Aristotle capital boston808.39K1.30%$25.48M
S&t bank/pa112.19K1.29%$4.06M
Third avenue management189.49K1.23%$5.97M
Tributary capital management343.96K0.96%$12.44M
Rice hall james & associates524.65K0.89%$16.54M
Bruce82.11K0.84%$2.59M

Top Buyers

HolderShares% AssetsChange
Sofinnova investments799.25K1.54%278.57K
Bnp paribas arbitrage, snc292.63K0.01%208.55K
Point72 asset management507.79K0.03%188.89K
D. e. shaw545.66K0.01%136.87K
Qube research229.71K0.01%131.63K

Top Sellers

HolderShares% AssetsChange
Woodline partners lp---423.83K
Armistice capital4.81M2.62%-384.00K
Polar capital1.00M0.17%-360.00K
Blackrock funding, inc. /de9.37M0.01%-316.66K
Millennium management30.47K0.00%-222.27K

New Positions

HolderShares% AssetsChangeValue
Norges bank125.55K0.00%125.55K$4.54M
Susquehanna portfolio strategies47.32K0.03%47.32K$1.49M
Gabelli funds17.59K0.00%17.59K$554.44K
Horizon investments14.00K0.01%14.00K$441.38K
Strs ohio13.70K0.00%13.70K$366.48K

Sold Out

HolderChange
Claris advisors, llc / mo /-1.00
Global financial private client-3.00
Mendota financial group-5.00
Hexagon capital partners-10.00
Stephens consulting-10.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 2025290-59,380,9950.51%1050.95%16311.64%80-15.79%
Mar 31, 2025286-2.72%59,007,517-0.81%1050.91%144-1.37%93-2.11%
Dec 31, 2024137-49.63%29,073,367-51.31%520.45%69-48.51%37-58.89%
Sep 30, 202427211.02%59,712,0472.23%1080.96%13415.52%9012.50%
Jun 30, 2024245-3.54%58,410,9433.44%1061.00%1169.43%80-15.79%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
iShares Core S&P Small-Cap ETF3.35M5.98%514.00
Macquarie Small Cap Core I2.08M3.72%-
Delaware Small Cap Core I2.00M3.62%-12.37K
Vanguard Total Stock Mkt Idx Inv1.68M3.00%-35.29K
Vanguard US Total Market Shares ETF1.68M3.00%1.91K
Vanguard Small Cap Index1.29M2.30%-8.71K
iShares Russell 2000 ETF1.27M2.26%-24.15K
Stephens SMID Select Growth1.13M2.01%-112.59K
Polar Capital Biotech S Inc1.00M1.79%-175.00K
Vanguard Explorer Inv905.65K1.62%-90.04K

Recent Insider Transactions


DateNameRoleActivityValue
Sep 12, 2025Mottola Frank SVP, Chief Tech. Ops. OfficerSell$229.35K
Sep 08, 2025Khattar Jack A. President, CEOSell$292.65K
Sep 05, 2025Khattar Jack A. President, CEOSell$2.56M
Aug 27, 2025Khattar Jack A. President, CEOSell$479.78K
Aug 28, 2025Khattar Jack A. President, CEOSell$1.09M

Insider Transactions Trends


DateBuySell
2025 Q3-16
2025 Q2--
2025 Q1-3
2024 Q4-8
2024 Q3-1

SUPN Ownership FAQ


Who Owns Supernus Pharmaceuticals?

Supernus Pharmaceuticals shareholders are primarily institutional investors at 105.99%, followed by 4.19% insiders and -10.18% retail investors. The average institutional ownership in Supernus Pharmaceuticals's industry, Specialty & Generic Drug Manufacturers Stocks, is 43.51%, which Supernus Pharmaceuticals exceeds.

Who owns the most shares of Supernus Pharmaceuticals?

Supernus Pharmaceuticals’s largest shareholders are Blackrock (10.39M shares, 18.90%), Blackrock funding, inc. /de (9.37M shares, 16.72%), and Vanguard group (6.15M shares, 11.15%). Together, they hold 46.78% of Supernus Pharmaceuticals’s total shares outstanding.

Does Blackrock own Supernus Pharmaceuticals?

Yes, BlackRock owns 18.90% of Supernus Pharmaceuticals, totaling 10.39M shares as of Jun 2024. This represents 0.01% of BlackRock's total assets, with a market value of 278M$. In the last quarter, BlackRock increased its holdings by 30.28K shares, a 0.29% change.

Who is Supernus Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Krensavage asset management is Supernus Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 7.88% of its assets in 472.38K Supernus Pharmaceuticals shares, valued at 14.89M$.

Who is the top mutual fund holder of Supernus Pharmaceuticals shares?

iShares Core S&P Small-Cap ETF is the top mutual fund holder of Supernus Pharmaceuticals shares, with 5.98% of its total shares outstanding invested in 3.35M Supernus Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools